STOCK TITAN

Dexcom (NASDAQ: DXCM) insider files to sell 1,012 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Dexcom insider Bridgette P. Heller filed a notice of proposed sale under Rule 144 covering 1,012 shares of common stock, with an aggregate market value of 68826.12. The shares are expected to be sold through Fidelity Brokerage Services on NASDAQ around 02/12/2026.

The securities were originally acquired on 09/29/2021 via restricted stock vesting as compensation. The filing also notes a prior sale on 11/12/2025 of 1,012 shares for gross proceeds of 58766.84. Dexcom had 390,016,272 shares outstanding when this notice was prepared.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the DXCM Form 144 filing by Bridgette P. Heller show?

The Form 144 shows Bridgette P. Heller intends to sell 1,012 Dexcom common shares under Rule 144. The shares were acquired via restricted stock vesting in 2021, and the planned sale is through Fidelity Brokerage Services on NASDAQ around 02/12/2026.

How many Dexcom (DXCM) shares are covered by this Form 144?

The notice covers a proposed sale of 1,012 Dexcom common shares. The filing lists an aggregate market value of about 68826.12 for this planned transaction, with trading expected on NASDAQ through Fidelity Brokerage Services as the executing broker.

When did the DXCM insider originally acquire the shares being sold?

The filing states the 1,012 shares were acquired on 09/29/2021 through restricted stock vesting. The consideration is described as compensation from the issuer, indicating these shares were part of an equity award rather than a cash purchase in the market.

What prior Dexcom (DXCM) share sales by this insider are disclosed?

The document reports a prior sale on 11/12/2025 of 1,012 Dexcom common shares, generating gross proceeds of 58766.84. This disclosure covers securities sold during the past three months for the same account, as required by Rule 144.

How many Dexcom (DXCM) shares were outstanding according to this notice?

The Form 144 lists 390,016,272 Dexcom common shares outstanding. This figure provides context for the relative size of the 1,012-share proposed sale, though it does not change the number of shares covered by the insider’s Rule 144 notice.

On which exchange will the Dexcom (DXCM) Rule 144 shares be sold?

The planned transaction identifies NASDAQ as the securities exchange for the 1,012 Dexcom common shares. Fidelity Brokerage Services LLC is listed as the broker handling the sale, with an approximate sale date of 02/12/2026 in the filing.
Dexcom Inc

NASDAQ:DXCM

DXCM Rankings

DXCM Latest News

DXCM Latest SEC Filings

DXCM Stock Data

25.38B
388.26M
0.42%
97.51%
2.83%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SAN DIEGO